Conversely, the STOP-AKI trial, carried out on 301 patients admitted to intensive care for sepsis, showed that recombinant human chimeric IALP/PALP therapy does not have a significant effect on short-term renal improvement. This evidence concerns the gene ALPP and Sepsis.